[{"id":"11f1db6a-6822-4ad4-9456-501ec049e598","acronym":"BEND-MBEC","url":"https://clinicaltrials.gov/study/NCT07189702","created_at":"2025-09-27T08:41:02.423Z","updated_at":"2025-09-27T08:41:02.423Z","phase":"","brief_title":"Plant-Based Nutrition for Breast or Endometrial Cancer","source_id_and_acronym":"NCT07189702 - BEND-MBEC","lead_sponsor":"University of Rochester","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-09-24"},{"id":"c72f3a57-80b1-4204-bf22-b374de81ba27","acronym":"","url":"https://clinicaltrials.gov/study/NCT07114653","created_at":"2025-08-16T14:08:30.041Z","updated_at":"2025-08-16T14:08:30.041Z","phase":"","brief_title":"The Role of POLE Mutation in High Risk Endometrial Cancer.","source_id_and_acronym":"NCT07114653","lead_sponsor":"Far Eastern Memorial Hospital","biomarkers":" POLE","pipe":" | ","alterations":" POLE mutation","tags":["POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-08-11"},{"id":"4298f366-bf0a-48de-9ba6-e0866564f4f9","acronym":"GerEC","url":"https://clinicaltrials.gov/study/NCT07066969","created_at":"2025-07-19T14:16:13.916Z","updated_at":"2025-07-19T14:16:13.916Z","phase":"","brief_title":"Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer","source_id_and_acronym":"NCT07066969 - GerEC","lead_sponsor":"European Institute of Oncology","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2025-07-15"},{"id":"c13b4cf9-274e-41ee-98c2-c2c6b58c5ea0","acronym":"","url":"https://clinicaltrials.gov/study/NCT07065552","created_at":"2025-07-19T14:15:38.690Z","updated_at":"2025-07-19T14:15:38.690Z","phase":"Phase 1","brief_title":"Tirzepatide in Obesity-Driven Endometrial Cancer","source_id_and_acronym":"NCT07065552","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-07-15"},{"id":"1d278134-0537-4b56-865d-be1ee7a40e61","acronym":"IREN","url":"https://clinicaltrials.gov/study/NCT07041606","created_at":"2025-06-28T13:39:22.517Z","updated_at":"2025-06-28T13:39:22.517Z","phase":"","brief_title":"An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation","source_id_and_acronym":"NCT07041606 - IREN","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-06-27"},{"id":"2cd0bb28-fe10-4b8b-9287-18ad8a95d0b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03990233","created_at":"2025-06-28T13:37:59.942Z","updated_at":"2025-06-28T13:37:59.942Z","phase":"Phase 1","brief_title":"A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT03990233","lead_sponsor":"OSE Immunotherapeutics","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 765063"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 04/17/2023","primary_completion_date":" 04/17/2023","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2025-06-26"},{"id":"277ff408-67f7-4d82-ab62-08c41100ac4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT07006103","created_at":"2025-06-07T14:39:04.179Z","updated_at":"2025-06-07T14:39:04.179Z","phase":"","brief_title":"PRECISION MEDICINE APPLIED TO THE STUDY OF ENDOMETRIAL CANCER: APPLICATION OF NGS FOR MOLECULAR CLASSIFICATION.","source_id_and_acronym":"NCT07006103","lead_sponsor":"Hospital Italiano de Buenos Aires","biomarkers":" POLE","pipe":"","alterations":" ","tags":["POLE"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-06-05"},{"id":"6ea988bc-bcb5-4786-9945-6bf50260a535","acronym":"","url":"https://clinicaltrials.gov/study/NCT06861855","created_at":"2025-09-07T01:51:21.194Z","updated_at":"2025-09-07T01:51:21.194Z","phase":"","brief_title":"Prognosis of METTL-14 in Endometrial Carcinoma","source_id_and_acronym":"NCT06861855","lead_sponsor":"Assiut University","biomarkers":" METTL14","pipe":"","alterations":" ","tags":["METTL14"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-03-06"},{"id":"fe61e59b-5160-4282-9285-2dc7eac8dfb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT06846099","created_at":"2025-02-27T07:07:42.576Z","updated_at":"2025-02-27T07:07:42.576Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903","source_id_and_acronym":"NCT06846099","lead_sponsor":"Risen (Suzhou) Pharma Tech Co., Ltd.","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 12/07/2022","start_date":" 12/07/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-25"},{"id":"08b2bc8f-c536-4ab4-95bd-8afe3b23bcd7","acronym":"NRG-GY026","url":"https://clinicaltrials.gov/study/NCT05256225","created_at":"2022-02-25T17:52:52.661Z","updated_at":"2025-02-25T12:28:40.900Z","phase":"Phase 2/3","brief_title":"Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer","source_id_and_acronym":"NCT05256225 - NRG-GY026","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 525","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-24"},{"id":"0cab49cd-f269-4139-a170-355e5106eb01","acronym":"","url":"https://clinicaltrials.gov/study/NCT05564377","created_at":"2022-10-03T15:56:45.241Z","updated_at":"2025-02-25T12:29:02.892Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","source_id_and_acronym":"NCT05564377","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • paclitaxel • Vectibix (panitumumab) • Koselugo (selumetinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Lumakras (sotorasib) • Mektovi (binimetinib) • nilotinib • fulvestrant • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 2900","initiation":"Initiation: 04/07/2023","start_date":" 04/07/2023","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 07/01/2030","study_completion_date":" 07/01/2030","last_update_posted":"2025-02-24"},{"id":"9c52b3ba-74cb-41b4-9ef2-03d1ced908cf","acronym":"IMGN151-1001","url":"https://clinicaltrials.gov/study/NCT05527184","created_at":"2024-02-01T02:20:14.331Z","updated_at":"2025-02-25T12:28:59.108Z","phase":"Phase 1","brief_title":"First in Human Study of IMGN151 in Recurrent Gynaecological Cancers","source_id_and_acronym":"NCT05527184 - IMGN151-1001","lead_sponsor":"AbbVie","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e opugotamig olatansine (IMGN-151)"],"overall_status":"Recruiting","enrollment":" Enrollment 423","initiation":"Initiation: 01/11/2023","start_date":" 01/11/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-24"},{"id":"251108c9-4fb9-4d2a-b2b3-ca1b2c0bb048","acronym":"","url":"https://clinicaltrials.gov/study/NCT01273168","created_at":"2021-01-18T05:09:01.740Z","updated_at":"2025-02-25T13:39:00.081Z","phase":"Phase 1","brief_title":"Endoxifen in Adults With Hormone Receptor Positive Solid Tumors","source_id_and_acronym":"NCT01273168","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Zonalta (Z-endoxifen hydrochloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"2dee9945-f549-4f20-8162-2f885a4bbaeb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05887492","created_at":"2023-06-02T14:06:23.752Z","updated_at":"2025-02-25T13:49:51.075Z","phase":"Phase 1/2","brief_title":"Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","source_id_and_acronym":"NCT05887492","lead_sponsor":"Tango Therapeutics, Inc.","biomarkers":" STK11","pipe":" | ","alterations":" STK11 mutation","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • TNG260"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 06/12/2023","start_date":" 06/12/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"48df85e5-b786-45f4-a391-eab53ca69d44","acronym":"AMPLIFY","url":"https://clinicaltrials.gov/study/NCT04000880","created_at":"2024-02-21T19:24:47.029Z","updated_at":"2025-02-25T13:48:43.597Z","phase":"","brief_title":"Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health","source_id_and_acronym":"NCT04000880 - AMPLIFY","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" IL6 • TNFA • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • CRP"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 603","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-02-21"},{"id":"dc06b6ac-0a69-4fa1-bf0d-291d63c5c2bc","acronym":"HERTHENA-PanTumor01","url":"https://clinicaltrials.gov/study/NCT06172478","created_at":"2023-12-15T19:20:07.848Z","updated_at":"2025-02-25T13:41:58.738Z","phase":"Phase 2","brief_title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT06172478 - HERTHENA-PanTumor01","lead_sponsor":"Daiichi Sankyo","biomarkers":" ERBB3","pipe":"","alterations":" ","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 02/26/2024","start_date":" 02/26/2024","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-21"},{"id":"0cde78dd-3c84-4aec-a573-c0c0e01915a1","acronym":"OPTEC","url":"https://clinicaltrials.gov/study/NCT03460483","created_at":"2021-01-18T17:03:29.688Z","updated_at":"2025-02-25T13:48:28.789Z","phase":"","brief_title":"Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care","source_id_and_acronym":"NCT03460483 - OPTEC","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" MSI • POLE","pipe":" | ","alterations":" POLE mutation","tags":["MSI • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1001","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2025-02-20"},{"id":"15959a9a-70ff-446f-ba15-1dcc1140abaf","acronym":"NRG-GY028","url":"https://clinicaltrials.gov/study/NCT05538897","created_at":"2022-09-14T18:56:09.184Z","updated_at":"2025-02-25T13:49:32.512Z","phase":"Phase 1/2","brief_title":"Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers","source_id_and_acronym":"NCT05538897 - NRG-GY028","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AKT1S1","pipe":"","alterations":" ","tags":["AKT1S1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ipatasertib (RG7440) • megestrol"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 03/31/2023","start_date":" 03/31/2023","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2025-02-20"},{"id":"9746c38a-e183-480a-bcc4-ea83361a9977","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554328","created_at":"2022-09-26T14:56:09.383Z","updated_at":"2025-02-25T13:49:33.072Z","phase":"Phase 2","brief_title":"Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554328","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation","tags":["KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Koselugo (selumetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 04/25/2023","start_date":" 04/25/2023","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2025-02-20"},{"id":"5325032a-dfb5-4381-8e59-f5e1418ec3ae","acronym":"DASH","url":"https://clinicaltrials.gov/study/NCT04704661","created_at":"2021-01-19T20:51:17.334Z","updated_at":"2025-02-25T14:02:10.901Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","source_id_and_acronym":"NCT04704661 - DASH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53 • ATM • RAS • CD4","pipe":" | ","alterations":" HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation","tags":["HER-2 • TP53 • ATM • RAS • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-19"},{"id":"ed7e0a8d-7121-41ed-982b-5af9f5bc5b3a","acronym":"NRG-GY025","url":"https://clinicaltrials.gov/study/NCT05112601","created_at":"2021-11-09T20:21:18.547Z","updated_at":"2025-02-25T14:16:28.432Z","phase":"Phase 2","brief_title":"Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","source_id_and_acronym":"NCT05112601 - NRG-GY025","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 06/02/2022","start_date":" 06/02/2022","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-18"},{"id":"03ad2ae1-62eb-4ee9-9973-fa23d5f2634d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05904496","created_at":"2023-06-15T17:08:23.801Z","updated_at":"2025-02-25T14:18:02.487Z","phase":"Phase 1","brief_title":"A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05904496","lead_sponsor":"BeiGene","biomarkers":" TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • BGB-30813"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/19/2023","start_date":" 07/19/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-17"},{"id":"1f5594ee-af51-418a-a186-3e2ddd1431f1","acronym":"BG-68501-101","url":"https://clinicaltrials.gov/study/NCT06257264","created_at":"2024-02-14T00:28:17.958Z","updated_at":"2025-02-25T14:18:45.977Z","phase":"Phase 1","brief_title":"A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors","source_id_and_acronym":"NCT06257264 - BG-68501-101","lead_sponsor":"BeiGene","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 03/11/2024","start_date":" 03/11/2024","primary_txt":" Primary completion: 02/28/2028","primary_completion_date":" 02/28/2028","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2025-02-17"},{"id":"734fb6ec-a3fe-4fc6-b873-fdb6107121be","acronym":"KEYNOTE-B21","url":"https://clinicaltrials.gov/study/NCT04634877","created_at":"2021-01-19T20:37:16.755Z","updated_at":"2025-02-25T14:08:01.972Z","phase":"Phase 3","brief_title":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","source_id_and_acronym":"NCT04634877 - KEYNOTE-B21","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • docetaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 990","initiation":"Initiation: 01/10/2021","start_date":" 01/10/2021","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-17"}]